Synektik_presentation_Q3_2023 FY_EN final.pptx

SYNEKTIK SA Synektik SA | Investor Presentation Q3 2023 FY

1. SYNEKTIK S.A. Investor Presentation Q3 2023 FY August 2024

2. Synektik in snapshot 2 Q3 FY 2023 Financial results | Investor presentation Company profile Integrator of innovative solutions for medicine Largest manufacturer and supplier of radiopharmaceuticals in Poland Research and Development Centre focused on developing innovative molecules and radiopharmaceutical products Developer of special medical software and applications Leading supplier of advanced medical technologies Provider of maintenance and measurement services Indexes WIG, mWIG40, WIGTECH, WIG-Poland ISIN PLSNKTK0001 Number of shares 8 529 129 Capitalisation (1) PLN 1.15bn Enterprise value (2) PLN 1.09bn P/E (3) 11.3 EV/EBITDA (4) 7.6 Market capitalisation and ratios calculated as of 1 August 202 4 Enterprise value = market capitalisation as of 1 August 202 4 + net debt as of 30 June 2024 Net profit adjusted for one-off items EBITDA adjusted for one-off items PLN 483 m REVENUE FROM SALES, Q1-Q3 FY2023 PLN 111 m AJDUSTED EBITDA Q1-Q3 FY2023

3. Highlights of Q3 FY2023 Sales of equipment and IT solutions – growing recurring revenue , expansion of the offer 21 % increase in revenue in Q 3 FY 2023, to PLN 114.2 million ; increase in recurring revenue by 6 3 %, to PLN 4 8 . 5 million Establishment of cooperation with Medical Microinstruments . GK Synektik has become the exclusive distributor of Symani microsurgery systems in Poland, the Czech Republic, Slovakia, Lithuania, Latvia, and Estonia Ex tension of cooperation with Intuitive. Synektik SA and Synektik Czech Republic, s.r.o. will be the exclusive distributors of Intuitive in Poland, the Czech Republic, and Slovakia at least until the end of 2029 Radiopharmaceuticals – growth in revenues and profitability PLN 9.8 million in revenue (excluding intra-group transactions) in Q3 FY2023 , up 21 % y/y Sa le increase of essential radiopharmaceuticals - PLN 5.7 million , up 13 % y/y R&D – Preparations to launch clinical trials in the USA Preparations to launch clinical trials in the United States, technology transfer in progress

4. 4 Q3 FY 2023 Financial results | Investor presentation Financial performance in Q3 FY2023 +22% +30% +34% 34 % increase in adjusted net result 21 % increase in total revenue from sales of equipment, IT solutions and the provision of services ( excluding intra-group transactions ) 21 % increase in revenue of the radiopharmaceuticals segment, excluding intra-group transactions 28 % increase in EBITDA of the equipment, IT and services segment, to PLN 31.7 mil l ion ; EBITDA margin at 28% 9 % increase in EBITDA of the radiopharmaceuticals segment, to PLN 3 . 4 mi l lion , EBITDA margin at 35%

5. PLN +7.5m Change in adjusted EBITDA PLN, million PLN, million PLN, million

6. 6 Q3 FY 2023 Financial results | Investor presentation Financial performance in Q1-Q3 FY2023 +55% +69% +66% 58 % increase in total revenue from sales of equipment, IT solutions and the provision of services ( excluding intra-group transactions ), to PLN 450.6m 22 % increase in revenue of the radiopharmaceuticals segment, excluding intra-group transactions , to PLN 32.3m 67 % increase in EBITDA of the equipment, IT and services segment, to PLN 108.3 mil l ion 52 % increase in EBITDA of the radiopharmaceuticals segment, to PLN 12.0 mi l lion 66% increase of adjusted net results PLN 3. million of negative balance of financ e income and costs, change by PLN -4 .2 milion ( mainly due to exchange rate differences )

7. 25.5 53.1 Group’s adjusted E BITDA i n FY 2020-2023 32.4 Summary 81 % increase in adjusted EBITDA for past 4 quarters, to PLN 142.8 million at 30.06.2024 EBITDA growth driven by: increase in sales of equipment used in therapy growing scale of recurring sales in both segments impact of operating leverage achieved thanks to a significant increase in the scale of the Group's activities

8. Group’s recurring sales i n FY 2020-2023 Dynamic growth of recurring revenue Drivers: Dynamically increasing demand for consumable parts and accessories for therapy equipment sold by the Synektik Group I ncrease in the value of post-warranty support services for the offered medical equipment Increase in the value of IT and measurement services provided Increase in demand for radiopharmaceuticals used in PET/CT examinations

9. Selected financial data PLN 000s Q3 FY 2023 Q3 FY 2022 Q1-Q3 FY 2023 Q1-Q3 FY 2022 Sales revenue 123 979 101 706 482 978 311 183 EBIT 20 673 17 036 82 650 44 847 EBIT margin 17% 17% 17% 14% Adjusted EBITDA 32 380 24 899 111 043 65 580 EBITDA margin 26% 24% 23% 21% Net profit 16 745 13 515 63 648 36 628 PLN 000s 30.06.2024 30.09.2023 Non-current assets, including: 147 628 131 291 Property, plant and equipment 50 468 37 663 Other intangible assets 44 394 50 345 Current assets, including: 202 929 168 624 Inventories 27 199 21 273 Trade receivables 95 214 79 659 Cash 76 665 62 663 Equity 171 357 134 201 Non-current liabilities 42 145 47 481 Liabilities under bank loans and borrowings - - Lease liabilities 13 160 13 848 Trade and other liabilities 4 233 11 580 Current liabilities, including: 137 055 118 233 Liabilities under bank loans and borrowings - 1 300 Lease liabilities 3 966 3 573 Trade and other liabilities 89 193 90 819 Net debt (59 540) (43 942) Total cash flow, including : 14 002 16 283 Operating cash flow 65 023 48 094 Surplus of cash over financial liabilities of PLN 60 million on 3 June 202 4 Increase in trade payables related to d eferred revenue s increase , (PLN 45.5 milliom ) related to the settlement of service contracts and the supply of consumables for therapeutic equipment. PLN 65.0 million in positive operating cash flow in Q1-Q3 FY2023 PLN 14 million in positive total cash flow s ( including dividend payout : PLN 25.8 million )

10. 10 Q3 FY 2023 Financial results | Investor presentation SYNEKTIK S.A. Medical equipment and IT solutions

11. Key information Synektik is a leading provider of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Core areas : Sale of medical equipment from several leading manufacturers, used in radiology, therapy and nuclear medicine Preparation and equipment for operating rooms (OR) and diagnostic or radiology centres Development of medical software and sale of licenses in the field of archiving and distribution of radiological images, teleradiology and administrative data Supply of specialist diagnostic and maintenance stations Maintenance and measurement services for medical equipment Innovative project: platform Zbadani.pl Medical equipment and IT solutions

12. 12 Medical equipment and IT solutions Dynamic revenue and profit growth 58% revenue growth year-over-year for the first 9 months of the 2023 financial year , reaching 450,6 million PLN 67% normalized EBITDA growth in Q1-Q3 of the 2023 financial year , reaching 108,3 million PLN 313,2 million PLN revenue from the sale of medical equipment in Q1-Q3 of the 2023 financial year ( compared to 204.9 milion PLN the previous year ) 71% growth in recurring revenue from the sale of services (service, warranty, IT) and the supply of consumable instruments and accessories in Q1-Q3 of the 2023 financial year , reaching 137,5 million PLN 102% CAGR of recurring revenue ( over the last 12 months ) in the last two years , reaching 170,1 million PLN as of June 30, 2024 . +102% CAGR

13. 13 Medical equipment and IT solutions Promising prospects for the coming quarters Secured orders worth 277.3 million PLN in the first 9 months of the 2023 financial year , including deliveries of: The ZAP-X system 18 da Vinci systems A package of imaging diagnostic devices The backlog value as of the end of June 2024 is approximately 20.5 million PLN, compared to 85.3 million PLN as of June 30, 2023 The value of d eferred revenue s ( resulting from the settlement of contract components for equipment deliveries ) was 45.5 million PLN as of the end of June ( compared to 10.5 million PLN as of June 30, 2023) In Q4 of the 2023 financial year , a contract was signed with the Voivodeship Specialist Hospital in Legnica for the delivery of two angiographs , two ultrasound machines , and the performance of adaptation works worth 9.9 million PLN A significant portion of active offers has been converted into contracts Expected significant increase in medical equipment sales in the coming quarters related to the commencement of spending funds from the Krajowy Plan Odbudowy ( National Recovery Plan)

14. 14 Da Vinci in Poland, Czech Republic, and Slovakia Approximately 3.3 thousand surgeries with the assistance of Da Vinci in the third quarter of 2023 in Poland ( up 106% y/y ), 10 thousand in the last 4 quarters ( up 102% y/y) Approximately 2.7 thousand surgeries with the assistance of Da Vinci in the third quarter of 2023 in the Czech Republic and Slovakia ( up 39% y/y ), 8.7 thousand in the last 4 quarters ( +36% y/y) 20 installations in the first 9 months of 2023, including 5 da Vinci systems installed in the third quarter of 2023. ( 3 in Poland , 2 in the Czech Republic ) Medical equipment and IT solutions

15. 30 Q2 2024 47 Q2 2024 Da Vinci serviced by GK Synektik Medical equipment and IT solutions * Being serviced by Synektik, including systems leased from Synektik da Vinci systems in Czech Republic and Slovakia * da Vinci systems in Poland* Warszawa Wrocław Białystok Poznań Kraków Siedlce Wieliszew Szczecin Gdańsk Gorzów Wlkp. Lublin Gdynia Katowice Bydgoszcz Rzeszów Łódź Toruń Usti nad Labem Pilzno Ceske Budejovice Hradec Kralove Velke Meziricí Brno Novy Jicin Ołomuniec Banska Bystrica Ostrava Praga Martin Jihlawa Liberec Bratysława Koszyce Kielce Leszno Zlin Częstochowa Słupsk Zielona Góra Olsztyn Pardubice Havirov Piaseczno Nowa Sól 1 3 kw. 2018 r. 4 4 kw. 2018 r. 8 4 kw. 2019 r. 13 4 kw. 2020 r. 16 4 kw. 2021 r. 17 1 kw. 2022 r. 22 4 kw. 2022 r. 40 4 kw. 2023 r. 16 1 kw. 2022 r. 19 4 kw. 2022 r. 29 4 kw. 2023 r. 77 Da Vinci systems serviced by GK Synektik

16. 16 Q3 FY 2023 Financial results | Investor presentation SYNEKTIK S.A. Radiopharmaceuticals

17. Key information Radiopharmaceuticals 50+ Number of employees Synektik Group products by diagnostic application Wide spectrum of tumours Prostate tumours Bladder tumours Parkinson's disease , neuroendocrine tumours Brain and extracranial tumours Breast and reproductive organ tumours Bone tumours Cholina FDG FLT PSMA Cholina FES FET DOPA Metaflu Axumin Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland Major producer of special radiopharmaceuticals 3 Production sites together with R&D Centre Location of cyclotrons for the production of radiopharmaceuticals used in PET studies Owned by Synektik Public Private Source: Own compilation based on data from the Supreme Audit Office, https://www.nik.gov.pl/aktualnosci/niecertyfikowane-radiofarmaceutyki.html (30.11.2021)

18. Radiopharmaceuticals Growing revenues and margins 22% increase in sales ( year-over-year ) in the first 9 months of 2023, up to 32.3 million PLN 27% , increase in sales of basic markers , up to 17.3 million PLN, resulting from the increase in the number of studies and changes in sales . 10% increase in sales of special markers , up to 6.0 million PLN 52% increase in EBITDA, up to 12.0 million PLN Increase in EBITDA segment profitability from 30% in the first 9 months of 2022 to 37% in the first 9 months of 2023) In the third quarter of 2023, agreements for the supply of radiopharmaceutical products and sets of reagents and materials for synthesis worth 2.1 million PLN were signed , and in the fourth quarter of 2023, agreements for the supply of other new radiopharmaceutal products worth 2.3 million PLN were signed .

19. 19 Q3 FY 2023 Financial results | Investor presentation SYNEKTIK S.A. Cardiotracer

20. Cardiotracer COMPETITIVE ADVANTAGES: Better image resolution and contrast Lower dose of radiation Quantitative analysis of myocardial blood supply in absolute terms Ability to image so-called difficult patients Shorter radiation retention time [1] DISCOVERY [2] PRE-TRIAL PHASE [3] CLINICAL TRIALS [4] APPROVAL BY THE FDA AND THE EMA PHASE I PHASE II PHASE III IN VIVO, IN VITRO TRIALS SAFETY OF USE, DOSIMETRY COMPARISON OF EFFICIENCY INVESTMENT COST RISK CARDIO PET MARKER Lead structure discovery, synthesis, evaluation HERE WE ARE Preparations to launch clinical trials in the United States, technology transfer in progress

21. 21 Q3 FY 2023 Financial results | Investor presentation SYNEKTIK S.A. Q&A SESSION

22. Cezary Kozanecki President of the Management Board , CEO [email protected] Dariusz Korecki Vice- President of the Management Board , CFO [email protected] Thank You !